{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:43Z","timestamp":1786119403748,"version":"build-2736575974"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1097\/coc.0b013e31815e4505","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T01:45:19Z","timestamp":1267062319000},"page":"237-243","source":"Crossref","is-referenced-by-count":17,"title":["Phase II Study of Combination Thalidomide\/Interleukin-2 Therapy Plus Granulocyte Macrophage-Colony Stimulating Factor in Patients With Metastatic Renal Cell Carcinoma"],"prefix":"10.1097","volume":"31","author":[{"given":"Robert J.","family":"Amato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Malya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics.","volume":"56","author":"Jemal","year":"2006","journal-title":"Cancer J Clin"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/ajcp\/103.5.624","article-title":"Adult renal epithelial neoplasms.","volume":"103","author":"Weiss","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2559.1993.tb00061.x","article-title":"Molecular differential pathology of renal cell tumours.","volume":"22","author":"Kovacs","year":"1993","journal-title":"Histopathology"},{"key":"R4-6-20210128","first-page":"390","article-title":"The natural history of renal carcinoma.","volume":"10","author":"Ritchie","year":"1983","journal-title":"Semin Oncol"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0022-5347(17)39992-5","article-title":"Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors.","volume":"143","author":"Giuliani","year":"1990","journal-title":"J Urol"},{"key":"R6-6-20210128","first-page":"1362","article-title":"Cancer: Principles and Practice of Oncology. 6th ed.","author":"Linehan","year":"2001"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"R8-6-20210128","first-page":"177","article-title":"Chemotherapy for renal cell carcinoma.","volume":"27","author":"Amato","year":"2000","journal-title":"Semin Oncol"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11912-002-0048-5","article-title":"Thalidomide: an antineoplastic agent.","volume":"4","author":"Amato","year":"2002","journal-title":"Curr Oncol Rep"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11934-001-0026-8","article-title":"Molecular-based therapies for renal cell carcinoma.","volume":"2","author":"Zisman","year":"2001","journal-title":"Curr Urol Rep"},{"issue":"suppl 13","key":"R11-6-20210128","first-page":"4","article-title":"Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.","volume":"16","author":"Dutcher","year":"2002","journal-title":"Oncology (Huntingt)"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/107327480200900404","article-title":"Immunotherapy of metastatic renal cell cancer.","volume":"9","author":"Fishman","year":"2002","journal-title":"Cancer Control"},{"issue":"suppl 1","key":"R13-6-20210128","first-page":"S93","article-title":"Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.","volume":"6","author":"Negrier","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N","article-title":"Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.","volume":"76","author":"Law","year":"1995","journal-title":"Cancer"},{"key":"R15-6-20210128","first-page":"86","article-title":"Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2\u2013based immunotherapy.","volume":"4","author":"Lee","year":"1998","journal-title":"Cancer J Sci Am"},{"issue":"suppl 7","key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/sonc.2002.33083","article-title":"Therapeutic options in the management of renal cell carcinoma.","volume":"29","author":"Glaspy","year":"2002","journal-title":"Semin Oncol"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","article-title":"Systemic therapy for renal cell carcinoma.","volume":"163","author":"Motzer","year":"2000","journal-title":"J Urol"},{"key":"R18-6-20210128","article-title":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology\u2014v. 1. Kidney Cancer.","author":"Motzer","year":"2003"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma.","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"R22-6-20210128","first-page":"148","article-title":"Cytokine therapy for metastatic renal cell carcinoma.","volume":"19","author":"Bukowski","year":"2001","journal-title":"Semin Urol Oncol"},{"issue":"suppl 1","key":"R23-6-20210128","first-page":"S55","article-title":"Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.","volume":"6","author":"Fisher","year":"2000","journal-title":"Cancer J Sci Am"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H","article-title":"Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.","volume":"80","author":"Bukowski","year":"1997","journal-title":"Cancer"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma.","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2003.02.014","article-title":"Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.","volume":"21","author":"Clark","year":"2003","journal-title":"J Clin Oncol"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0094-0143(21)00487-0","article-title":"Immunotherapy for metastatic renal cell carcinoma.","volume":"20","author":"Wirth","year":"1993","journal-title":"Urol Clin North Am"},{"key":"R28-6-20210128","first-page":"A6430","article-title":"Subcutaneous granulocyte macrophage colony stimulating factor (GM-CSF) with or without oral pentoxifylline in the treatment of patients with metastatic renal cell carcinoma.","volume":"14","author":"Stadler","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/(SICI)1097-0142(19960315)77:6<1149::AID-CNCR22>3.0.CO;2-0","article-title":"Phase II trial of subcutaneously administered granulocyte-macrophage colony stimulating factor in patients with metastatic renal cell carcinoma.","volume":"77","author":"Wos","year":"1996","journal-title":"Cancer"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bjc.1995.284","article-title":"The effects of granulocyte-macrophage colony-stimulating factor in tumor-infiltrating lymphocytes from renal cell carcinoma.","volume":"72","author":"Steger","year":"1995","journal-title":"Br J Cancer"},{"key":"R31-6-20210128","first-page":"319","article-title":"Clinical immunological effects of granulocyte macrophage-colony stimulating factor co-administered with interleukin-2: a phase 1 B study.","volume":"2","author":"Schiller","year":"1996","journal-title":"Clin Cancer Res"},{"key":"R32-6-20210128","first-page":"1544","article-title":"Histopathological, cytogenetic, and molecular characterization of renal cortical tumors.","volume":"51","author":"Presti","year":"1991","journal-title":"Cancer Res"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-5347(05)68259-6","article-title":"Histopathology and molecular genetics of renal tumors: toward unification of a classification system.","volume":"162","author":"Zambrano","year":"1999","journal-title":"J Urol"},{"key":"R34-6-20210128","first-page":"7349","article-title":"Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1, HIF-2, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3\u2032-kinase\/Akt signaling pathway.","volume":"61","author":"Blancher","year":"2001","journal-title":"Cancer Res"},{"key":"R35-6-20210128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"R36-6-20210128","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0959-8049(01)00290-8","article-title":"Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma.","volume":"37","author":"Rasmuson","year":"2001","journal-title":"Eur J Cancer"},{"key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"R38-6-20210128","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00001622-200011000-00009","article-title":"Current role of thalidomide in cancer treatment.","volume":"12","author":"Thomas","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor production by stimulated human monocytes.","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"R40-6-20210128","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1006\/exer.1997.0292","article-title":"Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.","volume":"64","author":"Kenyon","year":"1997","journal-title":"Exp Eye Res"},{"key":"R41-6-20210128","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0162-3109(95)00050-X","article-title":"Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.","volume":"31","author":"Geitz","year":"1996","journal-title":"Immunopharmacology"},{"key":"R42-6-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0162-3109(95)00039-7","article-title":"Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative.","volume":"31","author":"Shannon","year":"1995","journal-title":"Immunopharmacology"},{"key":"R43-6-20210128","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"key":"R44-6-20210128","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"issue":"suppl 13","key":"R45-6-20210128","first-page":"33","article-title":"Thalidomide for recurrent renal cell-cancer in a 40-year-old man.","volume":"14","author":"Amato","year":"2000","journal-title":"Oncology (Huntingt)"},{"key":"R46-6-20210128","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","article-title":"Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.","volume":"82","author":"Eisen","year":"2000","journal-title":"Br J Cancer"},{"key":"R49-6-20210128","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/JCO.2002.20.1.302","article-title":"Phase II trials of thalidomide for patients with advanced renal cell carcinoma.","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"R51-6-20210128","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/annonc\/mdf213","article-title":"Phase II trial of thalidomide in renal-cell carcinoma.","volume":"13","author":"Escudier","year":"2002","journal-title":"Ann Oncol"},{"key":"R52-6-20210128","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1054\/bjoc.2001.2025","article-title":"The treatment of advanced renal cell cancer with high-dose thalidomide.","volume":"85","author":"Stebbing","year":"2001","journal-title":"Br J Cancer"},{"key":"R55-6-20210128","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cncr.21737","article-title":"phase I\/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.","volume":"106","author":"Amato","year":"2006","journal-title":"Cancer"},{"key":"R60-6-20210128","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2002.20.5.1429","article-title":"Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma.","volume":"20","author":"Nathan","year":"2002","journal-title":"J Clin Oncol"},{"key":"R61-6-20210128","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","article-title":"Interleukin-2: inception, impact, and implications.","volume":"240","author":"Smith","year":"1988","journal-title":"Science"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0b013e31815e4505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:13:54Z","timestamp":1786040034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-200806000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e31815e4505","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}